Loading…
Employees: 2,822
Size China Shineway Pharmaceutical (2877.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $719M, the 670th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$7.46 on 6 Nov 2026.
Performance Over six months the shares fell 21.4%, against -17.2% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 17.7% over the last twelve months (peer median +0.5%); the operating margin is 24.5% (peer median 6.8%).
Valuation It trades at 7.2× forward earnings against a peer median of 26.9× (cheapest of 11).
Capital Return on invested capital runs 45.9 points above its cost of capital (7.8% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.97B | HK$3.40B | HK$4.10B | HK$4.99B | HK$4.59B |
| Revenue growth | — | -17% | -18% | +9% | — |
| Gross profit | HK$2.12B | HK$2.46B | HK$3.07B | HK$3.75B | HK$3.42B |
| EBITDA | HK$893M | HK$817M | HK$981M | HK$1.14B | HK$898M |
| Net income | HK$902M | HK$1.03B | HK$911M | HK$1.07B | HK$840M |
| Free cash flow | HK$1,000M | HK$1.28B | HK$1.07B | HK$939M | HK$1.24B |
| Capital expenditure | HK$197M | HK$215M | HK$152M | HK$159M | HK$151M |
| Total debt | n/a | HK$373M | HK$369M | HK$332M | HK$8.36M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2877.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -8.4% | 4th highest of 21 |
| 6-month return | -21.4% | -17.2% | 9th lowest of 21 |
| Distance from 52-week high | -28.7% | -39.3% | 3rd highest of 21 |
| Revenue growth (TTM) | -17.7% | +0.5% | 2nd lowest of 20 |
| Operating margin | 24.5% | 6.8% | 3rd highest of 19 |
| Forward P/E | 7.2× | 26.9× | cheapest of 11 |
| ROIC minus cost of capital | +45.9 pp | -0.2 pp | highest of 19 |
| Net debt / EBITDA | -9.4× | -2.3× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | n/a | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 438.0× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 48.6× | 20.4% | +12.1% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | n/a | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | n/a | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | n/a | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | n/a | -14.7% | +8.9% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |